



# ANTI-AGING PHARMACOLOGY

EDITED BY

**VITALY K. KOLTOVER**



# Contents

<i>Contributors</i>	xiii
<i>Preface</i>	xvii
<i>Acknowledgments</i>	xix

## 1. Geroscience—the concept 1

Alexander M. Vaiserman and Oleh V. Lushchak

1. Introduction	1
2. Geroscience and anti-aging medicine	2
3. Anti-aging pharmacology: state of the art, unresolved issues, and perspectives	3
4. Human health span extension: the longevity dividend	5
5. Could aging be a treatable medical condition?	6
6. Concluding remarks	7
Acknowledgment	9
References	9

## 2. Basic pathways and targets for anti-aging intervention 13

Mercedes Cano, Yiu To Yeung, Mario F. Muñoz, Antonio Ayala, Angélica Guerrero-Castilla and Sandro Argüelles

1. Introduction	13
2. Molecular and cellular mechanisms of aging	14
3. Overview of RNA quality control in aging	29
4. Conclusions and future perspectives	33
References	33

## 3. Omics approaches in aging research 41

Praveen K. Patnaik, Hanna Barlit, Sara Shoushtari and Vyacheslav M. Labunskyy

1. Introduction	41
2. Life expectancy clocks based on frailty indices	43
3. Epigenomics	43
4. Transcriptomics	46
5. Proteomics	50
6. Metabolomics	51

7. Ionomics	54
8. Cellular senescence	55
9. Gut microbiome	56
10. Conclusions and future perspectives	58
Acknowledgments	60
References	60
<b>4. Metformin</b>	<b>71</b>
Jared M. Campbell	
1. Introduction	71
2. Metformin and health	71
3. Metformin and longevity	78
4. Cause for caution	79
5. Mechanisms of action	81
6. Conclusion	83
References	83
<b>5. Rapamycin and rapalogs</b>	<b>89</b>
Dudley W. Lamming	
1. Inhibition of mTOR signaling extends life span and promotes health span	89
2. The risks of rapamycin	94
3. Why does rapamycin have side effects?	95
4. A simple model: inhibition of mTORC1 is beneficial, inhibition of mTORC2 is detrimental	97
5. Specific targeting of mTORC1 signaling to promote healthy aging	102
6. Conclusion	106
Acknowledgments	107
References	107
<b>6. Anti-aging effects of phenolic compounds</b>	<b>119</b>
María del Carmen Villegas-Aguilar, María de la Luz Cádiz-Gurrea, David Arráez-Román and Antonio Segura-Carretero	
1. Introduction	119
2. Alzheimer's disease	125
3. Other age-related diseases	128
4. Skin aging	136
5. Conclusions	142
References	143

<b>7. Curcumin</b>	<b>153</b>
Alexander M. Vaiserman, Oleh V. Lushchak, Alina Zayachkivska and Alexander Koliada	
1. Introduction	153
2. Phytochemicals as anti-aging therapeutics: mechanistic considerations	154
3. Curcumin: from chemical structure to therapeutic efficacy	155
4. Curcumin in aging-associated pathology prevention	157
5. Conclusions	168
Acknowledgment	168
References	168
<b>8. Pharmacology of NAD<sup>+</sup> boosters</b>	<b>177</b>
Nady Braidy and Perminder S. Sachdev	
1. Introduction	177
2. Overview of nicotinamide adenine dinucleotide biosynthesis pathways	178
3. Beneficial effects of nicotinamide adenine dinucleotide precursors in disease	180
4. Pharmacokinetics of nicotinamide adenine dinucleotide precursors	183
5. Conclusions and future perspectives	187
References	188
<b>9. Mitochondrial modulators</b>	<b>193</b>
Nataliia Naumova, Alexander Koliada, Nataliia Kuzub and Alexander M. Vaiserman	
1. Introduction	193
2. Mitochondria and aging-related signaling pathways	194
3. Mitochondria, telomeres, and aging	198
4. Age-related changes in the mitochondrial genome	199
5. Age-related alteration of mitochondrial permeability	200
6. Mitochondrial dynamics in aging	201
7. Mitochondrial metabolism and caloric restriction	202
8. Mitochondrial metabolism and exercise	205
9. Mitochondria-modulating potential of longevity compounds	206
10. Conclusion	210
References	210

<b>10. Nonsteroidal anti-inflammatory drugs</b>	<b>227</b>
Veronika Piskovatska, Viktoriia Buheruk, Olha Strilbytska, Alina Zayachkivska and Oleh V. Lushchak	
1. Introduction	227
2. Nonsteroidal anti-inflammatory drugs and diseases	229
3. Risks of long-term use of aspirin and other nonsteroidal anti-inflammatory drugs	235
4. Conclusions and future directions	237
Acknowledgments	238
References	238
<b>11. Senolytics in diseases: killing to survive</b>	<b>245</b>
Gaelle P. Massoud, Ali E. Eid, George W. Booz, Layale Rached, Andriy Yabluchanskiy and Fouad A. Zouein	
List of abbreviations	245
1. Discovery of cellular senescence	246
2. Senescence in cancer	249
3. Senescence in cardiovascular disease	251
4. Senolytics in metabolic disease	252
5. Senolytics in liver disease	254
6. Senolytics in kidney disease	255
7. Senolytics in lung disease	256
8. Senolytics in neurodegenerative disease	256
9. Senolytics in bone disease	258
10. Senolytics in skin disease	259
11. Conclusion	261
References	264
<b>12. Anti-aging skincare: the natural and organic way</b>	<b>269</b>
Idris Adewale Ahmed and Maryam Abimbola Mikail	
1. Introduction	269
2. Current global trends	270
3. The effects of skin aging	271
4. Changes in connective tissues and skin surface pH in aging skin	272
5. Intrinsic and extrinsic aging factors	273

6. Natural and organic skincare	274
7. Natural anti-aging ingredients groups	275
8. Conclusion	279
References	280
Further reading	284
<b>13. Protein kinase modulation for anti-aging intervention</b>	<b>285</b>
Mario F. Muñoz, Sandro Argüelles, Antonio Ayala and Francesco Marotta	
1. Introduction	285
2. Janus kinase/signal-transducing adapter model signaling pathway	287
3. P70 ribosomal protein S6 kinase	290
4. Hippo signaling pathway	293
5. Mitogen-activated protein kinase signaling pathway	295
6. Conclusions and future perspectives	298
References	299
<b>14. The anti-aging mechanism of Berberine associated with metabolic control</b>	<b>305</b>
Xiaofang Guo, Xiwen Xiong, Lijun Zhao, Genshen Zhong and Xiaofei Zhu	
1. Introduction	305
2. Mechanisms of berberine in targeting biological metabolic signaling	307
3. The clinical efficacy and side effects of berberine in age-related disease	313
4. Conclusions and future perspectives	316
Acknowledgments	316
References	317
<b>15. Growth hormone</b>	<b>329</b>
Andrzej Bartke and Savannah Brannan	
1. Introduction	329
2. Growth hormone	329
3. Impact of aging on the somatotrophic axis	330
4. Physiological meaning of age-related changes in hormone levels	331
5. Effects of growth hormone (GH) administration in GH-deficient vs endocrinologically normal adults	332
6. Treatment with growth hormone may affect epigenetic age	334
7. Conclusions	335

Acknowledgments	336
References	336
<b>16. Antioxidant pharmacology</b>	<b>341</b>
Vitaly K. Koltover and Tatjana A. Skipa	
1. Introduction	341
2. Free-radical hypothesis of aging: prelude	341
3. Free-radical malfunctions in oxidative metabolism	343
4. Free-radical redox-timer of aging in terms of system reliability theory	347
5. Antioxidant therapy: chemical background and experimental findings	350
6. Antioxidant therapy in light of system reliability theory	354
Acknowledgments	361
References	361
<i>Afterword: conclusions and outlook</i>	367
<i>Index</i>	373